Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2021

View Archived Issues

ROR1 TriKE candidate shows promise in preclinical models of prostate cancer

SLP76 deficiency leads to severe combined immunodeficiency in humans

FDA clears initiation of phase I study of TTAX-03 for facet joint pain in osteoarthritis

Preliminary topline data reported from phase IIb ALTISSIMO study of GB-102

JCR discontinues development of JR-031EB for epidermolysis bullosa

Sorrento and Mount Sinai to develop antibody combinations against SARS-CoV-2

Dovitinib demonstrates promising antitumor activity in preclinical model of osteosarcoma

First patient dosed in phase IIa study of MET-642 for the treatment of NASH

Surface Oncology and Merck & Co. collaborate on immune-oncology study of SRF-388

Pirtobrutinib demonstrates safety and efficacy in multiple B-cell malignancies

Hitgen discloses new IL1-7RA antagonists

Wigen Biomedicine Technology divulges KRAS mutant inhibitors

E.U. researchers patent viral compounds for synucleinopathies

Inorbit Therapeutics synthesizes FFAR1 agonists

Artios Pharma describes new POLQ inhibitors

FDA clears IND for phase II trial of Melior's tolimidone for COVID-19

At CROI, two-way street between HIV and SARS-CoV-2

Phase III trial results reported for blinatumomab in children with high-risk first-relapse B-ALL

BARDA to fund proof-of-concept studies of ibudilast for chlorine gas-induced lung damage

Initial phase I data on tri-specific COVID-19 antiviral treatment ensovibep in healthy volunteers

VBI begins phase I/II study of COVID-19 vaccine candidate VBI-2902

PI3K inhibitor umbralisib shows clinical activity in patients with indolent non-Hodgkin's lymphoma

Dosing begins in first-in-human study of CAN-106 for complement dysregulation diseases

Affimed continues REDIRECT trial of AFM-13 in PTCL after interim futility analysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...